TGF-β inhibitor, SB505124, resulted in a significant reduction of phosphorylated SMAD2 and inhibited the migration of fibroblasts stimulated by AF-MSC-hypoCM (Figure 4b). The gene discussed is SMAD2; the disease is atrial fibrillation.